FOX CHASE CANCER CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT05923190
- Locations
- 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Buprenorphine for Cancer Pain
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT05910190
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Adaptive Radiation for Abdominopelvic Metastases
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05880667
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT05800600
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT05800587
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT05800574
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
African Cancer Genome: GMD
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 1500
- Registration Number
- NCT05754658
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Couples' QOL in Metastatic Breast Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 112
- Registration Number
- NCT05636943
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Early Phase 1
Suspended
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT05498792
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Phase 3
Suspended
- Conditions
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 880
- Registration Number
- NCT05454280
- Locations
- 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
© Copyright 2024. All Rights Reserved by MedPath